FDA's Rejection of Moderna's mRNA Flu Vaccine Represents Harmful Regulatory Overreach
Source: Ronald Bailey. "Moderna's new mRNA flu vaccine is safe and effective. FDA won't even consider it.." February 12, 2026. reason.com
The Gist
The FDA wrongly rejected a new flu vaccine that works better than current ones, claiming the company didn't test it properly when they actually did. This decision blocks a promising medical advance and shows how government agencies hurt innovation.
Conclusion
The FDA's refusal to consider Moderna's safe and effective mRNA flu vaccine represents harmful regulatory overreach that suppresses beneficial medical innovation
Premises
- Moderna's mRNA-1010 flu vaccine demonstrated superior efficacy compared to standard flu vaccines, with 26.6% fewer influenza cases in clinical trials
- The vaccine showed comparable or superior immune responses to high-dose conventional vaccines while maintaining safety
- Moderna did compare their vaccine to appropriate standards of care (both standard-dose and high-dose vaccines), contrary to FDA claims
- mRNA technology offers significant advantages including rapid strain updates and flexible manufacturing for better virus matching
- The FDA's rejection was based on false premises about inadequate comparison studies
- This decision follows a pattern of FDA overcaution that has slowed medical innovation in multiple areas
Assumptions
- Clinical trial data accurately reflects real-world vaccine performance
- The FDA's stated reason for rejection is the actual reason rather than political influence
- Faster vaccine development and approval would result in net public health benefits
- Innovation in vaccine technology should be prioritized over extreme regulatory caution